A pretransplant minimal residual disease (MRD)–negative remission is one of the strongest predictors of favorable outcomes for HSCT in AML.26 In AML, NPM1 mutations are strongly predictive of a high MRD-negative response rate (88%) with venetoclax/azacitidine therapy.27-29 Furthermore, the low DNA-damaging potential of venetoclax/azacitidine was favored given the exquisite sensitivity of the nonhematopoietic FA cells to DNA-damaging agents. Here, NPM1 is linked to acute myeloid leukemia.